8 Participants NeededMy employer runs this trial

DSP-5336 for Blood Cancer

Recruiting at 1 trial location
HB
Overseen ByHolly Beever
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to evaluate the absorption, metabolism, and excretion of DSP-5336 following a single oral administration of the study drug in patients with hematologic malignancies whose disease has progressed after available standard therapies.

Are You a Good Fit for This Trial?

Inclusion Criteria

I am 18 or older and meet the required fertility or contraception conditions.
I am able to attend all study visits and stay for required monitoring.
* Able to comprehend and are willing to sign the ICF and abide by the study restrictions.
See 4 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Single oral administration of DSP-5336 to evaluate absorption, metabolism, and excretion

4-7 days

Follow-up

Participants are monitored for safety and effectiveness after treatment

30 days

Optional Continued Access

Participants may opt into continued access to DSP-5336

What Are the Treatments Tested in This Trial?

Interventions

  • DSP-5336

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Group I: Optional Continued AccessExperimental Treatment1 Intervention
Group II: DSP-5336 tablets and [14C]-DSP-5336 solutionExperimental Treatment2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Sumitomo Pharma America, Inc.

Lead Sponsor

Trials
244
Recruited
51,500+
Jatin Shah profile image

Jatin Shah

Sumitomo Pharma America, Inc.

Chief Medical Officer since 2024

MD from an unspecified institution

Tsutomu Nakagawa profile image

Tsutomu Nakagawa

Sumitomo Pharma America, Inc.

Chief Executive Officer since 2024

MBA from Waseda University